# Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

> **NCT01835145** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Recurrent Uveal Melanoma
- Stage III Uveal Melanoma AJCC v7
- Stage IIIA Uveal Melanoma AJCC v7
- Stage IIIB Uveal Melanoma AJCC v7
- Stage IIIC Uveal Melanoma AJCC v7
- Stage IV Uveal Melanoma AJCC v7

## Interventions

- **DRUG:** Cabozantinib S-malate
- **DRUG:** Dacarbazine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01835145
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-31
- **Primary completion:** 2016-10-21
- **Final completion:** 2019-11-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2022-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01835145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01835145, "Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01835145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*